Associate Professor, Medicine, University of Colorado School of Medicine

Oncology

Dr. Karl D. Lewis, MD

Karl Lewis is an expert in the field of Oncology. He graduated from Albany Medical College. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Karl Lewis is also a published doctor. He has 17 paper published. The most recent paper is: Association of sentinel lymph node diameter with melanoma metastasis. He accepts all Medicare patients.

Publications

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic Melanoma.
Association of sentinel lymph node diameter with Melanoma metastasis.
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
Retrospective Analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic Melanoma.
Effect of selumetinib vs chemotherapy on progression-free survival in uveal Melanoma: a randomized clinical trial.
New targeted therapies in Melanoma.
Long-term follow-up and survival of patients following a recurrence of Melanoma after a negative sentinel lymph node biopsy result.
Anti-CTLA4 Antibody Therapy Related Complications on FDG PET/CT.
Bridging the transition from Cancer patient to survivor: Pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program.
Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors.
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma.
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor.
Side population Cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
A neoadjuvant biochemotherapy approach to stage III melanoma: Analysis of surgical outcomes.
ABT-737 synergizes with Bortezomib to kill melanoma Cells.

Schools

Albany Medical College

Conditions Treated

Adrenal Gland Cancer
Anal and Rectal Cancer
Anemia
Basal Cell Carcinoma
View All

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Awards

CMS Meaningful Use Stage 1 Certification

Education

University of Colorado
University of California Irvine
Albany Medical College

Hospital

University of Colorado Hospital

Drug Facts

NPI NUMBER		1548350127
NPPES Provider LastName		LEWIS
NPPES Provider FirstName		KARL
NPPES Provider ZIPCode		800452545
NPPES Provider State		CO
Specialty Description		Medical Oncology
Total Claim Count		51.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1548350127
Last Name Of The Provider	LEWIS
First Name Of The Provider	KARL
View All

Similar Doctors

	Dr. Christopher H. Lieu, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert C. Doebele, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jonathan A. Gutman, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. William E. Daniel, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephen Leong, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. L Michael Glode, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Catherine E. Klein, MD This Doctor is OpenDoctor Recommended.
	Dr. Manoj Pillai, MD This Doctor is OpenDoctor Recommended.
	Dr. S Gail G. Eckhardt, MD
	Dr. Eun-Kyung Im, MD
	Dr. D Ross Camidge, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Wells A. Messersmith, MD This Doctor is OpenDoctor Recommended. This doctor has more publications